Daptomycin intravenous - Mylan/PhosphagenicsAlternative Names: TPM® Daptomycin
Latest Information Update: 10 Mar 2017
At a glance
- Originator Phosphagenics
- Developer Mylan; Phosphagenics
- Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics; Small molecules
- Mechanism of Action Cell membrane inhibitors; Cell wall inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Bacteraemia; Skin and soft tissue infections